Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

被引:5
|
作者
Luo, Jingming [1 ]
Zhang, Xianwen [1 ]
机构
[1] Hunan Agr Univ, Coll Biosci & Biotechnol, Changsha, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
基金
中国国家自然科学基金;
关键词
CAR-T therapy; TME; CRS; Boolean logic gate strategy; CAR-NK therapy; TUMOR-INFILTRATING LYMPHOCYTES; EFFICACY; ACTIVATION; ANTITUMOR; MICROENVIRONMENT; IMMUNOTHERAPY; PERSISTENCE; RECOGNITION; MOLECULE; MELANOMA;
D O I
10.3389/fonc.2024.1399544
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recent years have seen a marked increase in research on chimeric antigen receptor T (CAR-T) cells, with specific relevance to the treatment of hematological malignancies. Here, the structural principles, iterative processes, and target selection of CAR-T cells for therapeutic applications are described in detail, as well as the challenges faced in the treatment of solid tumors and hematological malignancies. These challenges include insufficient infiltration of cells, off-target effects, cytokine release syndrome, and tumor lysis syndrome. In addition, directions in the iterative development of CAR-T cell therapy are discussed, including modifications of CAR-T cell structures, improvements in specificity using multi-targets and novel targets, the use of Boolean logic gates to minimize off-target effects and control toxicity, and the adoption of additional protection mechanisms to improve the durability of CAR-T cell treatment. This review provides ideas and strategies for the development of CAR-T cell therapy through an in-depth exploration of the underlying mechanisms of action of CAR-T cells and their potential for innovative modification.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Innovations in cancer immunotherapy: chimeric antigen receptor T-cell therapy (CAR-T)
    Brown, Kevin
    Seftel, Matthew D.
    Hay, Kevin A.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2021, 193 (33) : E1300 - E1302
  • [32] CAR-T cell therapy for T cell malignances
    Watanabe, Keisuke
    CANCER SCIENCE, 2024, 115 : 812 - 812
  • [33] Biomarkers for CAR-T Cell Therapy
    不详
    TRANSFUSIONSMEDIZIN, 2024, 14 (03) : 123 - 124
  • [34] CAR-T Cell Therapy and Beyond
    Dotti, Gianpietro
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S4 - S4
  • [35] CAR-T Cell Therapy for Lymphoma
    Ramos, Carlos A.
    Heslop, Helen E.
    Brenner, Malcolm K.
    ANNUAL REVIEW OF MEDICINE, VOL 67, 2016, 67 : 165 - 183
  • [36] CAR-T Cell Therapy and the Neurointensivist
    Wijdicks, Eelco F. M.
    Rabinstein, Alejandro A.
    Lin, Yi
    NEUROCRITICAL CARE, 2024, : 691 - 694
  • [37] CAR-T cell therapy in Multiple Myeloma: current status and future challenges
    Swan, Dawn
    Madduri, Deepu
    Hocking, Jay
    BLOOD CANCER JOURNAL, 2024, 14 (01):
  • [38] A comprehensive review on the role of T cell subsets and CAR-T cell therapy in Aspergillus fumigatus infection
    Nasiri-Jahrodi, Abozar
    Barati, Mehdi
    Ahmadabad, Hasan Namdar
    Badali, Hamid
    Morovati, Hamid
    HUMAN IMMUNOLOGY, 2024, 85 (02)
  • [39] Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors
    Chen, Tong
    Wang, Mingzhao
    Chen, Yanchao
    Liu, Yutao
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [40] Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy
    Dreyzin, Alexandra
    Rankin, Alexander W.
    Luciani, Katia
    Gavrilova, Tatyana
    Shah, Nirali N.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (07) : 745 - 763